Ravi Shankar Kakaraparthy

Ravi Shankar Kakaraparthy

Auto-generated profile, based on publicly available information

Ravi Shankar Kakaraparthy

Aditya College of Pharmacy, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CKChandana Kamili
Chandana Kamili
RKRavi Shankar Kakaraparthy
Ravi Shankar Kakaraparthy
UVUma Maheshwararao Vattikuti
Uma Maheshwararao Vattikuti
The involvement of T-type calcium channels in cell proliferation and the role of sodium channels in cell migration have been extensively studied in angiogenesis. In the present study, flunarizine, a dual sodium/calcium channel blocker; was selected to evaluate its anti-angiogenic potential. This can be therapeutically beneficial in diseases caused by pathologically excessive angiogenesis. The anti-angiogenic activity of ion channel blocker was screened by chick chorioallantoic membrane assay (in ovo), rat aortic ring assay, endothelial cell proliferation assay, transwell migration assay, Matrigel cord-like morphogenesis assay (in vitro), and sponge implantation method (in vivo). The anti-angiogenic activity of the test drug was compared with the standard anti-angiogenic drug bevacizumab and, in addition, the test responses were compared with the angiogenic factor vascular endothelial growth factor at a maximal concentration of 500 pM. All the groups were compared with the control group using one-way ANOVA, followed by a post hoc test, Dunnett's test, to compare the mean of all the groups with the control mean. In the chick chorioallantoic membrane assay, the number of branching points and angiogenic score were evaluated and significant results were observed at 10-5 M and 10-4 M. In the aortic ring assay a reduction in the area of sprouts was observed with 5-10 μM and significant reductions in the weight of sponges, number of blood vessels formed, and hemoglobin content were observed at all three tested concentrations of flunarizine in the sponge implantation method. In the studies on human umbilical vein endothelial cells the test drug (1-100 nM) showed significant inhibition of proliferation and migration and a decrease in the network length of cord-like tubes in a dose-dependent manner. Flunarizine has significant anti-angiogenic action by inhibiting cell proliferation, migration, and cord-like tube formation, which resulted from blocking of the T-type calcium and sodium channels. Further studies on the structural modifications of flunarizine for repurposing this ion channel modulator will lead to treatment of the diseases due to excessive angiogenesis from the root cause.

17 October 2026
Verified
Book Chapter
Closed access
GKG. V. N. Kiranmayi
G. V. N. Kiranmayi
KRK. Ravishnakar
K. Ravishnakar
IMIndushekar Manjunatha
Indushekar Manjunatha
PKPriya Katiyar
Priya Katiyar
DBDarshan Huraliganganahalli Balaramegowda
Darshan Huraliganganahalli Balaramegowda
Vitiligo is an acquired disorder characterized by the autoimmune destruction of melanocytes, resulting in sharply demarcated depigmented patches. The purpose of this chapter, per the authors, is to synthesize the evolving therapeutic landscape of the disease. While physical morbidity is minimal, the psychosocial burden is substantial. Conventional treatments have relied on corticosteroids, calcineurin inhibitors, and phototherapy, but deeper mechanistic insight has enabled targeted immunotherapies. In particular, JAK–STAT pathway inhibition with agents like ruxolitinib halts interferon-gamma-driven melanocyte destruction to promote repigmentation. Phototherapy remains a mainstay for generalized disease, while surgical grafting and regenerative cell-based approaches benefit stable, refractory lesions. Ultimately, this chapter, per the authors, highlights the need for an integrated treatment strategy tailored to disease activity, anatomical site, and patient preferences.